The company's management is stellar.. they have been able to re brand Dixie's products which is quite promising. Regular Dixie, Dixie X (CBD with very small amounts of THC to allowed the CBD to take on a better affect), and Dixie Botanical's (Purely CBD). This re branding shows promise to what they will be able to achieve as they add to their portfolio of products.
The company has a lot going for it:
- Audit to a more reputable exchange, which will have them reporting fully reporting to SEC
- Once audit is complete 15 Million dollars in the form of a LOC will be accessible to MJNA
- Further capital will be accessible due to the up listing
- Eric Holders Comments
- Major contracts for the sale of its CBD it just harvested
- New products though acquisition via LOC and other sources of capital.
- Launch of CanChew gum
- Supreme Court Decision on rescheduling
- International expansion to Canada and Europe.
- Industrial Hemp is now legal to be grown in Colorado which will increase MJNA's profit margins for the coming quarters.
- Advertising opportunities and more media coverage.
- Expansion into more states such as Washington
- Increase sales due to legalization
- I hear on the board that the old CEO is going to cause this stock to be halted. If you do any research on the topic even taking into considerations this position in the hemp deposit corporation ... you know its not possible. And even if it was if would have to be clearly stated in their financial statements that it is a known risk.
- More licencing deals
- More distributions deals.
The list clearly is long. But I would be ignorant to leave out negatives.
- Banking is still a concern for the industry
- Full legalization nationally and big money like tobacco companies come in and dont make a deal with MJNA and push them out of business (highly unlikely as it will be a while for national legalization)
- Some sort of unknown fraud (this is a risk for any business that hasn't been audited even ones that have been audited.
- Management executes terribly (Executing well as of know)
- Federal Governmental Crack Down (Highly unlikely as they do not have the resources and the current governmental is very liberal)
- Europe or Canada rejects expansion into the region
I've left out some positives and negatives as I'm not going to sit here al day and list them. I just wanted to provided the point that the company has a lot going for them.... Its cheap from a multiple prospective considering growth, very clean financial statements and at 12 cents is a steal. The company will be trading in the lower .20 cent range by late February as it is an appropriate valuation for MJNA's current income and growth before Q4
Sentiment: Strong Buy
6.8% green today!!! Solid PR this morning!!! This is the kind of day I was hoping for. Our 10Q's will be getting progressively better with the elective procedure financing coming through as well. All is moving in the right direction. Three P's. Patience, patience, and patience.
Sentiment: Strong Buy
This is an excellent summary except that the Rescheduling decision is with the DC Appeals Court and not the Supreme Court. I live in DC and am watching this one very closely. You put together a great analysis.
Sentiment: Strong Buy
Thank you very much for the explanation. I have heard before here in Europe that people who don't like to have radiation and chemo they can get #$%$ and sometimes they can heal if cancer will not be find everywhere in the body.
I have read about Red Dice Holdings and it looks very good. When you have all the amino-acid in the oil , there are 9 together, that's very good and you have also Omega 3 and 6 and vitamines: A, D, B6 , E, K2 (very important against apoplexy) you have a wonderful product. They will sell it very easy. Everybody like to be healthy of course.
Excuse me for my English, I don't speak Englisch all the time.
Sentiment: Strong Buy
Cannabinoids are a group of 21-carbon–containing terpenophenolic compounds produced uniquely by #$%$ sativa and #$%$ indica species.[1,2] These plant-derived compounds may be referred to as phytocannabinoids. Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biologic activity are cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have significant analgesic and anti-inflammatory activity without the psychoactive effect (high) of delta-9-THC.
One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of tumors. During this 2-year study, groups of mice and rats were given various doses of THC by gavage. A dose-related decrease in the incidence of hepatic adenoma tumors and hepatocellular carcinoma was observed in the mice. Decreased incidences of benign tumors (polyps and adenomas) in other organs (mammary gland, uterus, pituitary, testis, and pancreas) were also noted in the rats. In another study, delta-9-THC, delta-8-THC, and cannabinol were found to inhibit the growth of Lewis lung adenocarcinoma cells in vitro and in vivo . In addition, other tumors have been shown to be sensitive to cannabinoid-induced growth inhibition.[5-8]
Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis invasion and metastasis.[9-12] One review summarizes the molecular mechanisms of action of cannabinoids as antitumor agents. Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death. These compounds have been shown to induce apoptosis in glioma cells in culture and induce regression of glioma tumors in mice and rats. Cannabinoids protect normal glial cells of astroglial and oligodendroglial lineages from apoptosis mediated by the CB1 receptor.
The effects of delta-9-THC and a synthetic agonist of the CB2 receptor were investigated in hepatocellular carcinoma (HCC). Both agents reduced the viability of hepatocellular carcinoma cells in vitro and demonstrated antitumor effects in hepatocellular carcinoma subcutaneous xenografts in nude mice. The investigations documented that the anti-HCC effects are mediated by way of the CB2 receptor. Similar to findings in glioma cells, the cannabinoids were shown to trigger cell death through stimulation of an endoplasmic reticulum stress pathway that activates autophagy and promotes apoptosis. Other investigations have confirmed that CB1 and CB2 receptors may be potential targets in non-small cell lung carcinoma  and breast cancer.
An in vitro study of the effect of CBD on programmed cell death in breast cancer cell lines found that CBD induced programmed cell death, independent of the CB1, CB2, or vanilloid receptors. CBD inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic, mammary cells.
CBD has also been demonstrated to exert a chemopreventive effect in a mouse model of colon cancer. In the experimental system, azoxymethane increased premalignant and malignant lesions in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In in vitro experiments involving colorectal cancer cell lines, the investigators found that CBD protected DNA from oxidative damage, increased endocannabinoid levels, and reduced cell proliferation.
Another investigation into the antitumor effects of CBD examined the role of intercellular adhesion molecule-1 (ICAM-1). ICAM-1 expression has been reported to be negatively correlated with cancer metastasis. In lung cancer cell lines, CBD upregulated ICAM-1, leading to decreased cancer cell invasiveness.
In an in vivo model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines. Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had antiangiogenic and antiproliferative effects. However, research with immunocompetent murine tumor models has demonstrated immunosuppression and enhanced tumor growth in mice treated with THC.[21,22]
In addition, both plant-derived and endogenous cannabinoids have been studied for anti-inflammatory effects. A mouse study demonstrated that endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic inflammation. As a result, a hypothesis that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of colorectal cancer has been developed.[24-27]
Sentiment: Strong Buy